FDA Seeks Stakeholder Participation in Animal Drug User Fee Reauthorization Meetings
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The notice opens a process for stakeholders to join regular FDA consultation meetings on the next renewal of the Animal Drug User Fee Act, which funds FDA’s review of new animal drugs through industry fees. Veterinary professionals, consumer and patient advocacy groups, scientific experts, and academic organizations that want a seat in these discussions should email FDA by June 1, 2026, with attendee contact details. Meetings are expected to start in June 2026 and continue at least every four months while FDA negotiates with regulated industry.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- FDA asks stakeholders to notify the agency if they want to join regular ADUFA reauthorization consultation meetings.
- Notifications must be emailed by June 1, 2026, with full attendee contact details and any accommodation needs.
- Meetings are expected to begin in June 2026 and continue at least every four months during FDA negotiations with regulated industry.
Obligations
What this law requires
Stakeholders that intend to participate in FDA’s periodic ADUFA reauthorization consultation meetings must submit a notification of intent by email to [email protected].
The notification email for participation must include complete contact information for each attendee, including name, title, affiliation, address, email address, telephone number, and any disability-related special accommodation requests.
Stakeholders wishing to participate should designate one or more organizational representatives who will commit to attending the consultation meetings and preparing for the discussions.
FDA must continue meeting with identified public stakeholders at least once every four months during ADUFA reauthorization negotiations with the regulated industry.